XW-17
XW-17 is a PARP14 inhibitor with an IC50 of 3.03 nM and selectivity over other PARP family members.XW-17 suppresses PARP14-mediated mono-ADP-ribosylation, engages and stabilizes endogenous PARP14 protein.XW-17 attenuates skin lesions and decreases expression of IL-4, IL-13, IgE, and IL-17A in an atopic dermatitis-like mouse model.XW-17 can be used for the research of atopic dermatitis.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Formel: C24H30N6O3
- Molecular Weight:450.53
-
Speicherung:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biologische Aktivität
Beschreibung
IC50 & Target
|
PARP14 |
In Vitro
XW-17 (1 h) potently and selectively inhibits purified PARP14 enzyme activity with an IC50 of 3.03 nM, showing a selectivity index exceeding 9900 over PARP1[1].
XW-17 shows excellent metabolic stability across rat plasma, mouse liver microsomes, rat liver microsomes, and human liver microsomes, with T1/2 values greater than 240 min in all tested systems[1].
XW-17 (5 μM; 2 h) exhibits satisfactory membrane permeability and low efflux in MDCK and Caco-2 cell models, with Papp A→B values of 16.32 × 10-6 cm/s and 20.49 × 10-6 cm/s, respectively[1].
XW-17 (0.001-3 μM; unspecified duration) engages and stabilizes endogenous PARP14 in IFN-γ-stimulated CFPAC-1 cells with an EC50 of 59.5 nM[1].
XW-17 (0.01-1 μM; 6 h pretreatment, 24 h IFN-γ stimulation) potently inhibits PARP14-mediated MARylation in a concentration-dependent manner in IFN-γ-stimulated CFPAC-1 and RAW264.7 cells[1].
XW-17 (up to at least 30 μM; 72 h) shows no significant cytotoxicity toward MCF-10A and AML-12 cells, with IC50 values greater than 30 μM[1].
XW-17 (5-30 μM) has low hERG potassium channel inhibitory activity, with 3.15% inhibition at 5 μM and 5.56% inhibition at 30 μM, indicating low cardiotoxicity risk[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:CFPAC-1 cells
-
Concentration:0.001-3 μM
-
Incubation Time:unspecified duration (IFN-γ stimulation)
-
Result:Induced a concentration-dependent upregulation of PARP14 protein expression, confirming target binding and stabilization, with an EC50 of 59.5 nM.
-
Cell Line:CFPAC-1 cells, RAW264.7 cells
-
Concentration:0.01-1 μM
-
Incubation Time:6 h pretreatment; 24 h IFN-γ stimulation
-
Result:Reduced intracellular MARylation signals in a concentration-dependent manner in both cell lines, indicating inhibition of endogenous PARP14 catalytic activity.
-
Cell Line:MCF-10A human mammary epithelial cells, AML-12 mouse hepatocytes
-
Concentration:up to at least 30 μM
-
Incubation Time:72 h
-
Result:Did not exhibit significant cytotoxicity, with IC50 values exceeding 30 μM in both cell lines.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB/c (male, 18−22 g, DNCB-induced atopic dermatitis)[1]
-
Dosage:25 mg/kg; 50 mg/kg; 100 mg/kg
-
Administration:i.p.; twice daily; 11 days
-
Result:Significantly reduced dermatitis score compared to model group at 25 mg/kg (P < 0.05), 50 mg/kg (P < 0.01), and 100 mg/kg (P < 0.001).
Achieved lower dermatitis score than positive controls RBN-3143 and Upadacitinib at 100 mg/kg.
Dose-dependently reduced histopathological abnormalities in dorsal skin, with 100 mg/kg dose achieving lowest histological score and outperforming Upadacitinib.
Significantly reduced protein levels of IL-4, IL-13, IL-17A in skin homogenates and serum IgE at 50 mg/kg and 100 mg/kg, with most pronounced inhibition at 100 mg/kg.
Dose-dependently suppressed mRNA levels of IL-31, TSLP, and GATA3 in dorsal skin.
Showed no significant effect on Th1 pathway-related cytokines (TNF-α, IL-6, IL-1β) at any dose.
Caused no significant body weight loss or histological abnormalities in major organs (heart, liver, spleen, lung, kidney).
Chemical Information
-
Molecular Weight 450.53
-
Formel C24H30N6O3
-
SMILES
CN1C=C(C=N1)CN2CCC(CC2)NC(CC3=NNC(C4=CC=C(C=C43)OCC5CC5)=O)=O
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Please store the product under the recommended conditions in the Certificate of Analysis.
Protokoll
-
RNA extraction experimental
By lysing cells, releasing RNA, and removing impurities such as proteins and DNA, high-purity RNA products are finally obtained. The commonly used traditional method is the guanidine isothiocyanate/phenol/chloroform method (Trizol), which is suitable for a variety of animal materials including animal tissues, microorganisms, cultured cells, etc., and most plant materials.
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
TPA/Croton Oil Ear Edema and Dermatitis
The TPA (12-O-tetradecanoylphorbol-13-acetate) and croton oil-induced mouse ear edema model is a well-established acute cutaneous inflammation system used to evaluate topical anti-inflammatory activity by measuring edema formation, neutrophil infiltration, vascular permeability, and cytokine-mediated skin responses in vivo. The inflammatory response is triggered by topical application of phorbol esters (TPA) or croton oil constituents, leading to rapid activation of protein kinase C signaling, leukocyte recruitment, and increased vascular permeability, which can be quantified by ear thickness, weight, dye extravasation, and biochemical markers such as myeloperoxidase (MPO) activity and pro-inflammatory mediators in ear tissue homogenates. This model is widely used for screening anti-inflammatory agents, where reductions in edema and inflammatory biomarkers reflect suppression of acute dermal inflammation and immune cell infiltration. Histological evaluation typically confirms epidermal
-
How to Choose the Right Model Animal
Choosing the right model animal is a validity-driven decision in which the species, strain, sex, age, genetic background, disease-induction method, outcome measures, and welfare burden must match the scientific question rather than laboratory tradition or convenience. A model should be selected by judging face validity, construct validity, and predictive validity: whether it resembles the human phenotype, whether it reproduces relevant mechanisms, and whether results are likely to predict human biology or treatment response. Animal studies often fail to translate because of species differences, weak disease resemblance, poor experimental design, inadequate reporting, publication bias, and underuse of randomization, blinding, and sample-size justification. Unresolved questions include how to rank competing models objectively, how much human-disease complexity must be reproduced for a given objective, and when non-animal systems such as organoids, ex vivo tissue, or computational models
Reinheit & Dokumentation
Verweise
Calculators
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)